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ABSTRACT
Introduction Surgery to remove the gallbladder 
(laparoscopic cholecystectomy (LC)) is the standard 
treatment for symptomatic gallbladder disease. One 
potential complication of gallbladder disease is that 
gallstones can pass into the common bile duct (CBD) 
where they may remain dormant, pass spontaneously 
into the bowel or cause problems such as obstructive 
jaundice or pancreatitis. Patients requiring LC are 
assessed preoperatively for their risk of CBD stones 
using liver function tests and imaging. If the risk is 
high, guidelines recommend further investigation and 
treatment. Further investigation of patients at low or 
moderate risk of CBD stones is not standardised, and the 
practice of imaging the CBD using magnetic resonance 
cholangiopancreatography (MRCP) in these patients varies 
across the UK. The consequences of these decisions may 
lead to overtreatment or undertreatment of patients.
Methods and analysis We are conducting a UK 
multicentre, pragmatic, open, randomised controlled trial 
with internal pilot phase to compare the effectiveness 
and cost- effectiveness of preoperative imaging with 
MRCP versus expectant management (ie, no preoperative 
imaging) in adult patients with symptomatic gallbladder 
disease undergoing urgent or elective LC who are at low 
or moderate risk of CBD stones. We aim to recruit 13 680 
patients over 48 months. The primary outcome is any 
hospital admission within 18 months of randomisation for 
a complication of gallstones. This includes complications of 
endoscopic retrograde cholangiopancreatography for the 
Strengths and limitations of this study
 ► This is a randomised controlled trial with randomi-
sation taking place using a secure internet- based 
system to ensure allocation concealment, which will 
ensure that patients allocated to each group have 
comparable baseline characteristics.
 ► The study includes an internal pilot phase with pro-
gression to the main study dependent on a number 
of criteria to ensure that the study will only proceed 
if it is viable to do so.
 ► Participants, clinicians and other hospital staff car-
ing for participants will not be blind to the study 
allocation.
 ► The criteria used to define low and moderate risk 
of common bile duct stones have been identified by 
clinicians within the study team, as there is no uni-
versal agreed definition of these terms.
 ► The study primary outcome will be derived from rou-
tine data sources, which should ensure high levels of 
data completeness but is reliant on timely approval 
of numerous applications to holders of routine data.
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treatment of gallstones and complications of LC. This will be determined 
using routine data sources, for example, National Health Service Digital 
Hospital Episode Statistics for participants in England. Secondary 
outcomes include cost- effectiveness and patient- reported quality of life, 
with participants followed up for a median of 18 months.
Ethics and dissemination This study received approval from Yorkshire & 
The Humber – South Yorkshire Research Ethics Committee. Results will be 
submitted for publication in a peer- reviewed journal.
Trial registration number ISRCTN10378861.
INTRODUCTION
Surgery to remove the gallbladder, known as laparo-
scopic cholecystectomy (LC), is the standard treatment 
for symptomatic gallbladder disease. LC is one of the 
most common operations undertaken globally, and 
around 70 000 LC operations are performed annually in 
England.1
One potential complication of gallbladder disease is 
that gallstones may pass from the gallbladder into the 
common bile duct (CBD). Once in the CBD, they may 
remain dormant, pass spontaneously into the bowel or 
cause problems such as obstructive jaundice, cholangitis 
or pancreatitis. If CBD stones are found, current guide-
lines recommend removal either before or during LC. 
Therefore, patients requiring LC are assessed preopera-
tively for their risk of CBD stones using a combination of 
liver function tests (LFTs) and imaging. If the risk is high, 
guidelines recommend further investigation and treat-
ment.2–6 Further investigation of patients at moderate or 
low risk of CBD stones is not standardised, and practice 
across the UK varies. Fewer than 10% of these patients 
actually have CBD stones.2–4 6 7 Consequently, surgeons 
make different decisions about investigation of the CBD; 
some surgeons choose to perform diagnostic imaging 
tests for these patients and others do not. This variation 
likely results in overtreatment or undertreatment, with 
significant risks to the patient in terms of morbidity, 
health- related quality of life (HRQoL) and costs to the 
health service.
A UK- wide audit found that a third of patients under-
going LC, irrespective of risk of CBD stones, had diag-
nostic imaging to test for CBD stones.7 This is most 
frequently performed with magnetic resonance cholan-
giopancreatography (MRCP) before admission for LC; 
however, some surgeons instead use intraoperative chol-
angiogram and other intraoperative ultrasound examina-
tions of the CBD. MRCP produces detailed images of the 
biliary and pancreatic ducts, involves a 1- hour hospital 
visit and costs the National Health Service (NHS) about 
£365. MRCP can identify CBD stones but may delay LC, 
which can have a detrimental effect on HRQoL and can 
lead to increased problems with gallstones or a more 
complex LC.8 If a CBD stone is identified during MRCP, 
extraction is most frequently performed before LC with 
an endoscopic retrograde cholangiopancreatography 
(ERCP). The risks and mortality associated with ERCP 
are significant,9 as is the cost to the NHS (about £1600). 
Not having MRCP avoids these risks but can lead to CBD 
stones remaining after surgery, which may also cause 
complications. Research is needed to establish whether 
it is appropriate for patients at low and moderate risk of 
CBD stones to proceed straight to LC without imaging 
the CBD with MRCP.
METHODS AND ANALYSIS
Aims and objectives
The Sunflower study aims to compare the effectiveness 
and cost- effectiveness of preoperative imaging with MRCP 
versus no MRCP (hereafter called expectant management 
(EM)) in patients with symptomatic gallbladder disease 
undergoing LC who are at low or moderate risk of CBD 
stones. The study will test the hypothesis that EM is not 
inferior to MRCP with respect to hospitalisation for treat-
ment for a complication of gallstones up to 18 months 
after randomisation.
The objectives are to estimate the:
1. Difference between groups in the proportion of partic-
ipants requiring a hospital admission for treatment of 
a complication of gallstones in the gallbladder or CBD.
2. Difference between groups with respect to a range 
of secondary outcomes, including patient- reported 
HRQoL, symptoms related to complications of gall-
stones in the gallbladder or CBD and symptoms re-
lated to complications associated with LC and, where 
applicable, ERCP.
3. Cost- effectiveness of MRCP compared with EM.
Study design
The Sunflower Study is a multicentre, pragmatic, open, 
randomised controlled trial with an internal pilot. The 
study has an embedded Qualitative Research Integrated 
within Trials Recruitment Intervention (QRI) to optimise 
informed consent and recruitment.10
There are two phases to the study:
Phase 1 (internal pilot): set- up and recruit from at least 
36 centres by month 16 of recruitment, with integrated 
QRI to optimise recruitment.
Phase 2: increase the number of centres to at least 50 
and continue recruitment using the methods established 
in phase 1, along with integrated QRI to optimise recruit-
ment and promote adherence in new centres.
Progression to phase 2 is conditional on the study 
demonstrating to the funder that: (A) at least 30 centres 
are open and recruiting; (B) at least 1750 participants 
have been randomised; (C) at least 90% of participants 
have followed their allocated pathway; and (D) the 
primary outcome can be identified reliably from routine 
data.
Setting
Recruitment will take place at a minimum of 50 NHS 
hospitals across the UK with a recruitment target of 13 680 
participants over a 48- month period (figure 1).
Study population
The target population is adults (18 years or older) with 
symptomatic gallbladder disease, scheduled and fit for 
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LC as an elective or urgent procedure who are at low 
or moderate risk of CBD stones. Low or moderate 
risk is defined as CBD diameter ≤8 mm on ultrasound 
scan (USS), bilirubin ≤50 µmol/L and alanine trans-
ferase (ALT) less than three times the upper limit of 
normal (≤3 ×ULN) and/or alkaline phosphatase (ALP) 
≤3 ×ULN. If the CBD cannot be visualised on USS, the 
patient may be recruited if no intrahepatic duct dilata-
tion is reported.
Patients are excluded if they are unable to undergo 
MRCP, have evidence of empyema or perforated gall-
bladder requiring urgent intervention, have had a 
previous gastric bypass, have had a previous MRCP or 
endoscopic USS within the last 3 months, have had any 
previous ERCP or have haemolytic disease. Patients 
must be willing to participate in follow- up and be able to 
provide informed consent.
Figure 1 The study schema. MRCP, magnetic resonance cholangiopancreatography.









pen: first published as 10.1136/bm




4 Clout M, et al. BMJ Open 2021;11:e044281. doi:10.1136/bmjopen-2020-044281
Open access 
Primary outcome
The primary outcome is any of the following:
i. Any hospital admission within 18 months of randomi-
sation for treatment of a complication of gallstones 
whether in the CBD or gallbladder.
ii. Complications during the admission for LC for 
the treatment for gallstones or any readmission for 
complications of the LC leading to a hospital day 
of >2 days. Complications will include, but not be 
limited to, return to theatre post- LC for any cause, 
percutaneous radiological drainage and ERCP for 
non- diagnostic reasons (eg, for a bile leak). It does 
not include a diagnostic ERCP performed following 
an MRCP where CBD stones were identified.
iii. Complications during any ERCP for the treatment 
for gallstones. Complications will include, but are not 
limited to, blood transfusion post- ERCP, percutane-
ous radiological drainage, treatment of a perforation 
occurring during ERCP, acute pancreatitis and other 
complications leading to a hospital stay of >2 days.
This outcome will be ascertained by linking the study 
data with routinely collected Hospital Episode Statistics 
(HES) and mortality data from NHS Digital for partic-
ipants recruited in England and the equivalent data 
sources for participants recruited in Scotland, Wales and 
Northern Ireland. Routine data sources contain informa-
tion on care provided to all patients treated in UK NHS 
hospitals.11 The final specification of qualifying events 
for identifying the primary outcome from these routine 
sources will be developed and validated during phase 1 of 
the study, through comparison of routine data with events 
identified from review of the medical records at 90 days 
post- LC.
Secondary outcomes
Patient- reported HRQoL will be measured using the 
EQ- 5D- 5L questionnaire.12 To minimise the overall study 
burden, about 20% of participants will be sampled and 
asked to complete questionnaires at multiple time points 
(table 1). A questionnaire pack will be provided to partic-
ipants containing the validated EQ- 5D- 5L questionnaire 
plus questions about the impact of abdominal pain on 
work, productivity and primary healthcare use.
Other secondary outcomes include items that cover 
the domains in the core outcome set for patients with 
symptomatic gallstones and hospital resource use in the 
18 months after randomisation collected from routine 
data sources.13 14
Sample size
The sample size of 13 680 has been chosen to test the 
hypothesis that EM is non- inferior to MRCP with respect 
to the primary outcome. In estimating the sample size, we 
have considered the proportion of patients that would be 
expected to experience the primary outcome, as identi-
fied in the CholeS audit (5%–10%) and through explo-
ration of HES data.7 This includes patients at high risk of 
CBD stones. The consensus among clinicians on the study 
team was that the non- inferiority margin should be set at 
1.5%, that is, that the risk of the primary outcome with 
EM should not exceed 8.5% assuming a risk of 7% after 
MRCP. A study of 13 680 participants will provide 90% 
power to test the non- inferiority hypothesis for a 7% event 
risk with MRCP and 80% power to test the non- inferiority 
hypothesis for a higher event risk of 8.5%, assuming 2.5% 
one- sided statistical significance and a 1:2 allocation ratio 
(MRCP:EM). The 20% sample of participants providing 
HRQoL data will be stratified by centre. This sample of 
2736 participants will have >90% power to detect a small 
effect size of 0.12 standard deviation between groups on 
the EQ- 5D- 5L questionnaire.
Recruitment
Recruiting centres will screen LC waiting lists and gall-
bladder clinic lists for potentially eligible patients. 
Potential participants will also be identified from urgent 
inpatient and ambulatory care admissions and ward 
handovers. Eligible patients will be provided with study 
information and will have the opportunity to ask ques-
tions before being approached for their informed consent 
(see online supplemental material 1). Patients who feel 
they have had insufficient time to consider the study 
will be invited to take home a consent form and ques-
tionnaire pack (where applicable) and to complete and 
return them by post. Details of all patients approached 
for the study and reasons for non- participation will be 
documented.
Randomisation
Randomisation will be performed by an authorised 
member of the local research team using a secure 
internet- based system to ensure allocation concealment. 
The allocation will be computer generated and stratified 
by centre.
Participants will be randomised to MRCP or EM in a 
1:2 ratio. This ratio has been selected to reflect current 
levels of MRCP provision (13%–26% of patients at low or 
moderate risk of CBD stones currently undergo MRCP).7
Interventions
The study interventions are preoperative MRCP and EM.
Participants allocated to the MRCP group will have an 
MRCP before the date of their listed LC. The study will 
make no changes to the usual hospital radiology proto-
cols used for MRCP and will not impose any timelines 
for the MRCP or any subsequent interventions. If a CBD 
stone is found on MRCP, surgeons can manage extraction 
according to their usual practice. The study does not stip-
ulate removal of identified CBD stones, and any further 
interventions are at the discretion of the clinician. If an 
ERCP is requested, it will be performed as a separate 
inpatient procedure before admission for LC.
Participants allocated to EM will be listed for LC 
without any preoperative imaging. If MRCP is carried out, 
for example, due to a change in a participant’s clinical 
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circumstances after randomisation, this will be docu-
mented as a crossover.
In both groups, intraoperative imaging will not be 
permitted unless there is an anatomical reason to do so, 
or if a CBD stone is found on MRCP. Any deviations from 
the protocol will be recorded and monitored.
Data collection
Data will be collected by the local study team at baseline, 
before, during and after LC and at hospital discharge 
(table 1). Data collection will be from hospital records, 
including operative notes, and will include information 
on any pre- LC MRCP and ERCP and any intraoperative 
imaging. Data will either be collected onto a paper case 
report form and transcribed into a secure electronic study 
database or entered directly into the database. During 
phase 1, safety data will also be collected from hospital 
records 90 days post- LC by the local study team.
Linkage to routine data
With consent, participant identifiers will be sent to NHS 
Digital and equivalent organisations for participants 
recruited outside of England. These organisations will 
match and extract pseudonymised data for these partic-
ipants for all episodes of hospital care for a minimum 
of 18 months from the point of randomisation and for a 
period of 12 months prior to randomisation. The data will 
include inpatient and critical care episodes, accident and 
emergency department attendances, outpatient appoint-
ments, diagnostic imaging investigations and mortality.
MRCP quality assurance
To address the challenge of MRCP technique varying across 
participating centres, images and reports for a random 
10% sample of participants who receive an MRCP will be 
transferred for independent quality assurance review by 
consultant radiologists. The MRCP examinations will be 
assessed for the type of sequences performed, the diag-
nostic quality of the images and level of concordance with 
the hospital reports. These data will provide an overview 
of current NHS practice and the overall quality of MRCP 
examinations, as well as characterising variation in MRCP 
technique in study centres.
Statistical analysis
The study will be analysed on an intention- to- treat (ITT) 
basis, that is, outcomes will be analysed according to 
the allocated treatment pathway irrespective of future 
management and events, and every effort will be made 
to include all randomised participants. Non- adherence 
to the treatment allocation will be documented. The 
primary analysis will follow the Consolidated Standards of 
Reporting Trials guidelines for a non- inferiority study.15 
An analysis according to treatment pathway followed will 
also be performed for the primary outcome. As recom-
mended, both analyses will be considered when assessing 
whether the hypothesis is met.16 The primary outcome 
will be compared using survival methods to allow for 
censoring. For participants without a qualifying primary 
outcome event, they will be censored at the time the 
dataset was compiled. If more than one qualifying event 
occurs (eg, two hospital admissions for gallstone- related 
complications), time to the first event will be used. The 
frequency of each element of the primary outcome 
and reasons for admission, where applicable, will be 
described. Secondary outcomes will be compared using 
a mixed model for continuous outcomes or a generalised 
linear regression model for binary outcomes, adjusted 
for prerandomisation measures when available. For 
secondary outcomes measured at multiple time points, 
changes in treatment effect with time since randomi-
sation will be assessed by adding a treatment by time 
interaction to the model and comparing models using a 
likelihood ratio test. Model fit will be assessed, and alter-
native models and/or transformations (eg, to induce 
normality) will be explored where appropriate. Sensi-
tivity analyses using multiple imputation for missing data 
will be explored. Analyses will be adjusted for centre, and 
treatment differences will be reported with 95% confi-
dence intervals.
A detailed analysis plan will be prepared. There is no 
intention to compare any outcomes between groups at 
the end of phase 1; only descriptive statistics about eligi-
bility, recruitment and adherence will be summarised 
at this time to determine whether the study satisfies the 
progression criteria.
Exploratory analyses will include:
i. Relationship between number and size of stones seen 
on MRCP and patient outcome (cohort undergoing 
MRCP only).
ii. Relationship between stones removed under ERCP 
or not (eg, ‘necessary’ vs ‘unnecessary’ ERCP) and 
patient outcomes (cohort undergoing ERCP only).
Subgroup analyses will evaluate the primary outcome 
in patients defined by characteristics. The main subgroup 
analysis will be in patients with low versus moderate risk of 
CBD stones, which will be defined following phase 1. This 
definition is expected to be a composite of baseline LFTs, 
baseline CBD diameter on USS and LC admission type 
(elective or urgent). Further subgroups will be defined:
i. Patients referred for elective surgery versus patients 
undergoing urgent surgery.
ii. Patients with normal LFTs at baseline (ie, low risk) 
versus patients with abnormal (outside of local Trust 
upper and/or lower normal limits) LFTs at baseline 
(ie, moderate risk).
iii. Patients with a history of pancreatitis versus patients 
with no history of pancreatitis.
Health economic analysis
The primary economic evaluation will compare NHS 
costs and patient outcomes, measured by quality- adjusted 
life years (QALYs), between the groups on an ITT basis. 
This analysis will explore whether the initial savings due 
to not using MRCP are offset by higher treatment costs 
and worse patient outcomes due to LC complications 
and/or retained stones.









pen: first published as 10.1136/bm




7Clout M, et al. BMJ Open 2021;11:e044281. doi:10.1136/bmjopen-2020-044281
Open access
English NHS tariffs will be used to estimate the costs.17 
These tariffs are based on Healthcare Resource Groups 
(HRGs) and distinguish between open/laparoscopic, 
elective/urgent and day case/inpatient surgery. However, 
they are not sufficiently granular to measure the impact 
on costs of small differences in theatre time or postsur-
gical length of stay, which might be evident between 
groups. Therefore, micro- costing may also be used to 
estimate the incremental costs of LC. HRG codes, NHS 
tariffs and national unit costs will be used to estimate all 
other care costs during follow- up.18 National Institute for 
Health and Care Excellence recommended EQ- 5D- 5L 
value sets for England will be used with linear interpola-
tion between time points and adjustment for baseline to 
calculate QALYs.19 20
Costs and outcomes beyond 12 months will be discounted 
at standard rates.21 Missing cost and EQ- 5D- 5L data will 
be described, and multiple imputation techniques will be 
used as appropriate. The incremental cost per QALY of 
MRCP versus EM over the 18- month follow- up period will 
be estimated, and bootstrapping techniques will be used 
to estimate 95% CIs. Regression analyses will be used to 
estimate the incremental net monetary benefit and cost- 
effectiveness acceptability curve of MRCP at conventional 
thresholds after controlling for key baseline covariates.22 In 
a secondary economic analysis, we will estimate the cost per 
gallstone- related readmission avoided. Sensitivity analyses 
will explore the robustness of the conclusions to plausible 
differences in key costing assumptions. If there is evidence 
that costs and outcome differences between groups persist 
between 6 and 18 months, a simple extrapolation model to 
estimate cost- effectiveness beyond 18 months will be consid-
ered. The impact of care pathways on patient productivity 
costs will be described in secondary analyses. A health 
economics analysis plan will detail analytical methods.
Safety
In accordance with Good Clinical Practice guidelines, the 
occurrence of adverse events will be monitored carefully 
and recorded in detail.
Following LC, transient postoperative complications 
are not unexpected and often delay the patient’s hospital 
discharge. These complications are classified as expected 
events in this study. There are also some known compli-
cations of ERCP and MRCP, which are also classified as 
expected events. Any event classified as expected will not 
require expedited reporting to the sponsor or research 
ethics committee (REC), unless in the event of a partici-
pant death. Unexpected serious adverse events, including 
participant deaths, will be reported to the study sponsor 
and coordinating centre.
Data on adverse events will be collected from randomi-
sation until hospital discharge after LC, or for 9 months 
postrandomisation for participants who do not undergo 
LC for any reason.
Patient and public involvement statement
We will work in close partnership with patients and 
members of the public throughout all phases of the 
Sunflower Study. The study funding proposal was devel-
oped in collaboration with our patient/public contrib-
utor coapplicant who has experience of gallstone 
investigations/surgery. Two public contributors have 
been appointed to the study steering committee (SSC), 
who participate in all committee meetings.
Feedback from patient and public contributors on study 
rationale and design was sought during the prefunding 
and postfunding stages of the study. Topics discussed 
included experiences of gallstone investigations and bile 
duct imaging, advantages/disadvantages of bile duct 
imaging, relevance/importance of a randomised trial and 
barriers/facilitators to recruitment, randomisation and 
follow- up to inform development of the study protocol.
A patient/public advisory group has been established, 
and patient and public involvement activities have 
been conducted regularly throughout the set- up and 
running of the study. Consultations with patient/public 
contributors have covered a diverse range of issues. For 
example, patient/public contributors have been involved 
in drafting and revising study participant information 
leaflets and consent forms to improve participant infor-
mation provision. We have also consulted with patient/
public contributors regarding proposed protocol amend-
ments, resulting in the introduction of an additional 
postal/remote consent pathway to optimise recruit-
ment during the COVID-19 pandemic. Interviews with 
patient/public contributors have also been conducted 
to explore concerns around study participation and 
attending hospital during the pandemic. Most partici-
pants were in favour of recruitment restarting, helping to 
inform subsequent decisions around restarting the study. 
Further patient/public activities have been undertaken 
to explore additional strategies for optimising recruit-
ment (including the codevelopment of a patient- facing 
clinic recruitment poster), patients’ experiences/burden 
of study participation, and layout and content of the 
Sunflower Study website.
We will work closely with patient and public contrib-
utors to develop a strategy for sharing the study find-
ings with participants, future patients, service users and 
members of the wider public. This will include consider-
ation of disseminating findings using a range of materials 
and methods, such as plain language summaries, news-
letters, videos, social media, websites and patient support 
groups.
Risk of bias
Participating centres will aim to screen all adult patients 
with symptomatic gallbladder disease who are scheduled 
and fit for LC. We expect that the recruited patients will 
be generalisable to the wider population. Patients allo-
cated to each group will have comparable baseline char-
acteristics as randomisation will take place after consent 
via a secure website with allocation concealment. Alloca-
tions will be stratified by centre to minimise confounding.
The primary outcome is objective and will be obtained 
from routinely collected data sources. This is important 









pen: first published as 10.1136/bm




8 Clout M, et al. BMJ Open 2021;11:e044281. doi:10.1136/bmjopen-2020-044281
Open access 
as participants, clinicians and other hospital staff caring 
for participants will be unblinded. Attempts to blind 
participants by undertaking ‘dummy’ MRCP in those 
randomised to EM would have added significant addi-
tional research costs and created logistical issues. Because 
‘dummy’ MRCP would cause a similar delay to LC as actual 
MRCP, it would also prevent the study from assessing the 
impact of this on outcomes.
The risk of missing data has been minimised by using 
routinely collected data for the primary outcome and 
by undertaking regular review of missing data captured 
explicitly for the study.
We do not expect patient- reported outcomes to be at 
risk of bias, since we do not anticipate that participants 
will have preferences or expectations about the use of 
MRCP. We aim to promote uncertainty about the effects 
of the two interventions by providing information that 
describes the risks and benefits of each intervention. This 
information has been reviewed by a public and patient 
involvement group and informed by the experiences of 
the QRI researchers.
Study management and oversight
Preparation of study documents, site initiation visits and 
training, day- to- day running of the study and monitoring 
of centres are managed by the Clinical Trials and Evalua-
tion Unit, Bristol Trials Centre. A study executive group is 
overseeing the study and meets regularly to review mile-
stones. A data monitoring and safety committee meets 
biannually to review data. An SSC oversees the study 
and has ultimate responsibility for any decision about its 
continuation. Membership of the study oversight commit-
tees is described in the Acknowledgements section.
Changes to the study protocol
Two substantial amendments have been approved by the 
REC. The first, in April 2019, added the option of postal 
consent, and the second, in December 2019, revised some 
inclusion/exclusion criteria and clarified information 
relating to withdrawals in line with the Health Research 
Authority guidance.
DISCUSSION
The main challenge facing the Sunflower Study is the 
recruitment target of 13 680 participants. Recruitment 
started 1 month later than planned in January 2019. The 
initial focus was to open centres to recruitment, with a 
target of 36 centres recruiting within phase 1. The study 
has already exceeded this target. As of 23 August 2020, 
48 centres were open to recruitment, and 2040 partici-
pants had been randomised. The QRI will be key to opti-
mising recruitment, providing training at investigators 
meetings and recruitment tips for staff at participating 
centres.23 24 With a 48- month recruitment period, it 
will also be key for the study to keep centres engaged. 
Initiatives include the use of an active Twitter account, 
regular recruitment updates and centre targeted emails, 
biannual newsletters and annual investigators’ meetings. 
It will also be important to remain aware of other relevant 
research that could impact on the study. The study team 
will undertake annual literature reviews.
The study includes patients who are scheduled for LC 
as either an elective or urgent procedure. It is important 
to ensure that both pathways are represented to promote 
generalisability of the study results, but it is recognised 
that recruitment of urgent patients is challenging. These 
patients can be admitted at any time of day and over 
weekends when research nurses may not be available to 
approach patients and receive consent. As of 23 August 
2020, 77.8% of randomised participants were elective 
referrals and 22.2% were from urgent admissions. The 
study is keen to involve surgical trainees in the recruit-
ment process and is participating in the National Insti-
tute for Health Research associate Principal Investigator 
scheme.25 During study training, the local team is encour-
aged to consider recruitment from the urgent pathway, 
and the ratio of elective to urgent patients recruited is 
being monitored. The study feels that surgical trainees 
will be critical to the successful recruitment of urgent 
patients. Discussions from an investigator meeting iden-
tified that the inclusion criterion, ALT and/or ALP less 
than 2 ×ULN, was disproportionally excluding urgent 
patients, and so this was amended to 3× ULN. The impact 
of this amendment will be monitored.
For the study results to be generalisable, we aim 
to recruit both patients classified as being at low and 
moderate risk of CBD stones. Low- risk patients are 
defined as those with bilirubin, ALT and ALP all within 
the normal range of their local Trust. As of 23 August 
2020, 67% of randomised participants were classified as 
being at low risk and 33% as moderate risk.
Another major challenge will be obtaining routinely 
collected data from England, Wales, Northern Ireland and 
Scotland. Applications to obtain routinely collected data 
are complex and time consuming, and a different appli-
cation process is required for each nation. The coordi-
nating centre has considerable experience in completing 
these applications, but they must be successful and timely 
for the primary outcome to be determined and health 
economic analyses to be completed.
The primary outcome for the study is composed of 
three elements. The first will compare hospital admissions 
for treatment of gallstone complications in the 18 months 
after randomisation. The second and third elements will 
compare postoperative complications of LC and compli-
cations of ERCP. These two elements are important to 
measure, as there is evidence of increased rates of some 
complications (eg, biliary leakage) in patients with 
retained stones post- LC.26 This may have relevance to 
participants randomised to EM. It is also possible that 
participants are overtreated with MRCP, and any subse-
quent ERCP, and suffer avoidable complications. These 
elements will help inform study results and application 
in practice. The primary outcome will be reported both 
overall and by each individual element.
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Study status
Recruitment to the study started in January 2019 and is 
due to complete in January 2023. The current protocol is 
version 3.0 dated 25 November 2019. Relevant regulatory 
approvals will be obtained for amendments to the study 
documentation. Information relating to amendments will 
be disseminated to relevant parties via email, newsletter 
and an electronic study management system.
Ethics and dissemination
This study was reviewed and given a favourable opinion 
by Yorkshire & The Humber – South Yorkshire REC on 
the 10 December 2018 (REC reference: 18/YH/0358). 
Each participating centre is required to provide evidence 
of local confirmation of capacity and capability prior to 
starting recruitment to the study. Informed consent to 
participate will be obtained from all study participants. 
Participants have the right to withdraw from the study 
at any time and, if they do withdraw, will be treated 
according to standard local hospital procedures. Routine 
data will continue to be collected for withdrawn partici-
pants, unless the participant explicitly asks for this data 
collection to stop.
The study findings will be disseminated through peer- 
reviewed publications and international conferences and 
will be provided to study participants. A study specific 
Twitter account will be used to promote the study, 
provide updates on milestones and disseminate study 
findings. After study completion and reporting, the tech-
nical appendix, statistical code and dataset generated 
from the study will be available from the corresponding 
author on request. The request must include a speci-
fication of the data requested and justification for that 
request (ie, a statement of purpose for which the data are 
required). The data may not be released unless all Bristol 
Trials Centre and sponsor requirements are fulfilled 
(eg, protocol, sample size calculation, REC and Health 
Research Authority approval if appropriate, a collabora-
tion arrangement in place between the sponsor and the 
external body).
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